Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016.
Scott D GrosseThuy Quynh N DoMichelle VuLisa B FengJay G BerryGregory S SawickiPublished in: Pediatric pulmonology (2018)
Per-patient expenditures for privately-insured patients with CF almost doubled during 2010-2016; specialty drugs were largely responsible for this increase, with a major contribution from new, genotype-targeted CFTR modulator medications.